Alaunos Therapeutics to Report Fourth Quarter and Full Year 2021 Financial Results on March 30, 2022
Alaunos Therapeutics, Inc. (TCRT) will announce its fourth-quarter financial results for 2021 on March 30, 2022, before U.S. market open. Following this, a conference call and webcast will be held at 8:30 a.m. ET for a corporate update and financial review. Investors can access the call by dialing in or through a live webcast on the company’s website. Alaunos specializes in oncology-focused cell therapies, leveraging its Sleeping Beauty gene transfer platform, and has collaborations with notable institutions like MD Anderson Cancer Center and the National Cancer Institute.
- Clinical-stage oncology-focused cell therapy company with a unique gene transfer platform.
- Strategic collaborations with leading cancer research institutions enhance credibility and potential.
- None.
Insights
Analyzing...
HOUSTON, March 16, 2022 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq: TCRT), today announced that it will report financial results for the fourth quarter ended December 31, 2021 on Wednesday, March 30, 2022, before the open of U.S. markets. Following the announcement, the Company will host a conference call and webcast at 8:30 a.m. ET to provide a corporate update and review the financial results.
The conference call can be accessed by dialing 844-309-0618 (United States) or 661-378-9465 (International) with the conference code 9091406. A live webcast may be accessed using the link here, or by visiting the “Investors” section of the Alaunos website at www.alaunos.com. After the live webcast, the event will be archived on the Company’s website for approximately 30 days after the call.
About Alaunos Therapeutics, Inc.
Alaunos is a clinical-stage oncology-focused cell therapy company, focused on developing T-cell receptor (TCR) therapies based on its non-viral Sleeping Beauty gene transfer platform and its unique cancer hotspot Library, covering common tumor-related mutations in key oncolytic genes including KRAS, TP53 and EGFR. The Company has clinical and strategic collaborations with The University of Texas MD Anderson Cancer Center and the National Cancer Institute. For more information, please visit www.alaunos.com.
Investor Relations Contact:
Alex Lobo
Stern Investor Relations
Alex.lobo@sternir.com
FAQ
When will Alaunos Therapeutics report Q4 2021 financial results?
How can I access the Alaunos Therapeutics conference call?
What is the focus of Alaunos Therapeutics?
What partnerships does Alaunos Therapeutics have?
